



New GSK Program Reduces Out-of-Pocket Costs for HIV Meds

November 11, 2008

GlaxoSmithKline announced today the launch of a new Patient Savings Card to help eligible people living with HIV reduce their out-of-pocket medication expenses. Through this new program, patients are eligible to save up to \$100 every month for each of their prescriptions involving antiretrovirals (ARVs) produced by GSK, for up to two years.

HIV-positive people are eligible for the new GSK-funded program if they pay any amount of cash for their ARVs, such as insurance co-payments or full-price payments, and their prescriptions are not covered by Medicaid, Medicare, a state AIDS Drug Assistance Program (ADAP) or other government-funded assistance program. Retired people who are Medicare eligible and enrolled in an employer-sponsored health plan or drug benefit plan are not eligible. Additionally, Massachusetts residents are eligible only if they are paying the entire cost of their ARVs themselves.

Although the [Patient Savings Card](#) can only be used for ARVs manufactured by GSK—options include [Lexiva](#) (fosamprenavir), [Epzicom](#) (abacavir plus lamivudine), [Ziagen](#) (abacavir), [EpiVir](#) (lamivudine) and [Retrovir](#) (zidovudine)—it can be used to defray the out-of-pocket costs of multiple medications. For example, a person who is taking Norvir-boosted Lexiva plus Epzicom would save up to \$100 on his or her co-payments for both prescriptions—up to \$200 total. The co-payment associated with the Norvir prescription would not be covered.

Patients can enroll in the program by visiting their doctors and asking for a Patient Savings Card and then presenting it to their local pharmacist along with their prescriptions for eligible GSK ARVs.

© 2026 Smart + Strong All Rights Reserved.

<http://beta.docker.poz.com/article/hiv-patient-copay-15602-7206>